Welcome to our store
MOTS-c has become an increasingly interesting subject in mitochondrial and metabolic research. Unlike many peptides studied only as conventional protein products, MOTS-c is a mitochondria-derived peptide encoded by mitochondrial DNA. Researchers have investigated its relationship with metabolic regulation, exercise-related signaling, mitochondrial biology, and cellular stress responses.
However, an important distinction is often lost in online discussions: evidence from laboratory and animal studies is not the same as evidence from human clinical research.
That distinction is especially important in 2026 because a Phase 2a clinical study of MOTS-c is now registered and recruiting participants. At the same time, FDA materials continue to identify significant gaps in human exposure and safety information for compounded MOTS-c products.
This article examines where the science currently stands.
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a 16-amino-acid peptide encoded within the mitochondrial genome.
Researchers first described MOTS-c in 2015 and subsequently investigated its potential role as a mitochondrial-derived signaling molecule. Reviews of the research describe mitochondria not simply as energy-producing structures but also as sources of signaling molecules that can communicate with other cellular systems.
This makes MOTS-c particularly interesting for researchers studying the relationship between:
For researchers evaluating mitochondrial-derived compounds, understanding peptide identity, purity, and batch consistency is also important. Vitale Peptide discusses these considerations in its research library and provides research compounds for laboratory use.
One major reason for studying MOTS-c is its connection with cellular metabolic signaling.
Preclinical research has associated MOTS-c with pathways involved in metabolic adaptation and stress responses. Researchers have also investigated relationships between MOTS-c and AMPK-related signaling, skeletal muscle metabolism, and exercise-associated responses.
Importantly, these findings should not be interpreted as proof that administering MOTS-c produces the same effects in humans.
The research question is more specific:
Can observations from cellular and animal models be translated into reproducible human findings?
That is one of the questions current clinical research is beginning to address.
Preclinical research has produced several findings that explain why MOTS-c continues to attract scientific attention.
In a 2021 study published in Nature Communications, researchers reported that MOTS-c influenced metabolic and stress-response pathways in mice. The study examined young, middle-aged, and older mice and reported effects on physical performance, skeletal muscle metabolism, and adaptation to metabolic stress. The researchers also examined endogenous MOTS-c expression in humans following exercise.
Other laboratory and animal studies have investigated MOTS-c in different biological models.
For example, a 2024 Cell Reports study examined MOTS-c in a mouse model of diet-induced nonalcoholic steatohepatitis. Researchers reported changes involving mitochondrial metabolism, inflammation, fibrosis, and Bcl-2 signaling. However, this was a preclinical study, meaning its findings cannot be directly interpreted as evidence of a treatment effect in people.
Research published in 2025 also investigated MOTS-c in cardiac models involving type 2 diabetes and mitochondrial respiration. Again, these findings provide mechanistic and preclinical information rather than established human therapeutic outcomes.
Human research on MOTS-c is more limited than the preclinical literature.
Some human studies have measured naturally occurring MOTS-c rather than administering an investigational MOTS-c product.
For example, researchers studying acute exercise found changes in circulating mitochondrial-derived peptides, including MOTS-c, following exercise protocols in humans. The study included separate endurance-exercise, resistance-exercise, and control groups.
Another human study investigated relationships between MOTS-c, insulin, lipids, and exercise in healthy participants and women with polycystic ovary syndrome. Researchers found that lipid infusion increased circulating MOTS-c while insulin attenuated some of that response. The researchers also reported that eight weeks of moderate exercise did not change circulating MOTS-c levels in the studied groups.
More recently, a 2025 human observational study involving 77 participants examined circulating MOTS-c levels in people with obstructive sleep apnea. The researchers reported associations between serum MOTS-c levels and measures including BMI, apnea-hypopnea index, and oxygen desaturation index. However, an observational association does not establish that MOTS-c causes or treats the condition.
This illustrates why human evidence needs to be separated into different categories.
A human study can measure naturally occurring MOTS-c without testing whether administering MOTS-c is beneficial.
That distinction matters.
The existing human literature includes observational studies and studies measuring endogenous MOTS-c responses. These studies help researchers understand the biology of the peptide, but they are not equivalent to randomized clinical trials of an administered MOTS-c product.
One of the most important recent developments is the registration of NCT07505745, titled MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity.
According to ClinicalTrials.gov, this is a Phase 2a randomized, double-blind, placebo-controlled study sponsored by Hudson Biotech. The study is listed as recruiting and has an estimated enrollment of 120 participants.
The study is designed to investigate whether 12 weeks of investigational MOTS-c treatment affects insulin sensitivity compared with placebo.
Researchers plan to assess outcomes including:
The study record indicates that the treatment period is followed by a safety follow-up period.
Crucially, the trial does not yet provide results.
Therefore, it would be premature to describe MOTS-c as proven effective for insulin sensitivity or any other medical outcome based on this trial.
View the MOTS-c Phase 2a study on ClinicalTrials.gov
Safety is an important area where the available evidence remains incomplete.
FDA’s current review materials state that the agency has not identified human exposure data involving drug products containing MOTS-c administered through any route and that important information regarding potential safety concerns remains unavailable. FDA also identifies potential concerns related to immunogenicity and peptide-related impurities and characterization for certain compounded preparations.
Read the FDA’s current information on MOTS-c
Several mechanisms have been proposed or investigated in MOTS-c research.
One area involves AMPK-related metabolic signaling. AMPK is an important cellular energy-sensing pathway, and preclinical research has investigated how MOTS-c may interact with metabolic stress responses involving this pathway.
Another area is mitochondrial communication.
MOTS-c is particularly interesting because its origin in the mitochondrial genome provides an example of mitochondria-derived signaling that may influence processes beyond traditional energy production. Researchers have investigated interactions between mitochondrial signals, nuclear gene regulation, metabolism, and cellular stress responses.
Recent research has also examined MOTS-c in the context of cellular membrane repair. A 2024 study reported that MOTS-c was associated with TRIM72-related membrane repair mechanisms and examined these relationships using both human observations and in-vitro experiments.
These mechanisms remain active research questions rather than established therapeutic pathways.
The current evidence can be summarized simply:
| Evidence Type | What Researchers Have Learned |
|---|---|
| In-vitro research | MOTS-c can influence specific cellular pathways under controlled laboratory conditions |
| Animal research | Studies have investigated metabolism, exercise adaptation, mitochondrial function, and other biological endpoints |
| Human observational research | Researchers have measured endogenous MOTS-c and investigated associations with exercise and metabolic conditions |
| Human interventional research | A Phase 2a randomized trial is currently investigating administered MOTS-c |
| Clinical efficacy | Not yet established from the current trial |
| Comprehensive human safety profile | Not yet established |
This distinction is essential when evaluating online claims about MOTS-c.
Despite growing interest, several questions remain open.
Researchers still need more information about:
The ongoing Phase 2a trial may provide important information, but its results will need to be evaluated once they become available.
The growing interest in emerging compounds also highlights the importance of research-material quality.
Researchers need confidence that the material used in an experiment has the expected identity and characteristics. Batch-to-batch consistency, analytical documentation, and Certificates of Analysis can all contribute to better research documentation.
For more information, see Vitale Peptide’s existing resources on peptide batch consistency, Certificates of Analysis, and research peptide selection criteria.
You can also explore the [Vitale Peptide research peptide catalog] or review the available MOTS-c research compound for laboratory research.
Explore Vitale Peptide research compounds
View the Vitale Peptide MOTS-c research compound
MOTS-c is an emerging mitochondrial-derived peptide with a growing body of preclinical and human observational research.
Animal and laboratory studies have investigated metabolic regulation, exercise-related responses, mitochondrial biology, cellular stress pathways, and other mechanisms. Human studies have primarily helped researchers understand naturally occurring MOTS-c and its relationships with physiological conditions.
The research landscape is now moving into an important stage: a Phase 2a randomized clinical trial is recruiting participants to investigate administered MOTS-c and insulin sensitivity. However, results are not yet available, so clinical efficacy should not be assumed.
At the same time, FDA materials emphasize that important human safety and exposure information remains limited for compounded MOTS-c products.
For researchers, the most useful approach is therefore to view MOTS-c as an emerging research compound whose biological mechanisms and potential applications are still being investigated.
MOTS-c should not be described as an FDA-approved drug for treating or preventing disease. FDA materials currently identify important gaps in human exposure and safety information.
Yes. ClinicalTrials.gov currently lists NCT07505745, a Phase 2a randomized, double-blind, placebo-controlled study of investigational MOTS-c in adults with prediabetes and overweight or obesity. The study is listed as recruiting.
Yes. Human research has examined naturally occurring MOTS-c levels and relationships with exercise, metabolic factors, and other physiological measurements. These studies are different from clinical trials evaluating administered MOTS-c.
Not yet. The current Phase 2a trial is specifically designed to investigate this question, and the ClinicalTrials.gov record does not currently report results.
Researchers are investigating MOTS-c in areas including mitochondrial signaling, metabolic regulation, exercise-related adaptation, cellular stress responses, and mitochondrial-derived peptide biology.
Researchers can consult primary literature through PubMed and review registered clinical studies through ClinicalTrials.gov.
Search MOTS-c research in PubMed
This article is provided for educational and scientific research-information purposes only. It summarizes published research and publicly available regulatory and clinical-trial information and is not medical advice. Vitale Peptide products are intended for laboratory research purposes only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of disease. Readers should evaluate primary scientific literature, applicable regulations, laboratory requirements, and current regulatory information before conducting research.
© 2026 All rights reserved
